In the United States, resistance to linezolid has been monitored and tracked since 2004 through a program named LEADER, which () was conducted in 60 medical institutions throughout the country.
The intrinsic resistance of most Gram-negative bacteria to linezolid is due to the activity of efflux pumps, which actively "pump" linezolid out of the cell faster than it can accumulate [REF].